Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03518112
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideBiological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateBiological: OfatumumabDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03488225
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 9
- Registration Number
- NCT03370601
- Locations
- 🇫🇷
CHRU, Hôpital Claude Huriez, Lille, France
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 60
- Registration Number
- NCT03286634
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AllopurinolDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: Vincristine SulfateDrug: DexamethasoneDrug: Pegylated L-AsparaginaseDrug: MethotrexateProcedure: Bone Marrow Aspiration and BiopsyDrug: CyclophosphamideDrug: MercaptopurineBiological: RituximabDrug: ThioguanineDrug: DoxorubicinOther: Laboratory Biomarker AnalysisBiological: Inotuzumab Ozogamicin
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 310
- Registration Number
- NCT03150693
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 560
- Registration Number
- NCT03020030
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase PegolProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Dexrazoxane HydrochlorideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideDrug: Imatinib MesylateDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: PegaspargaseDrug: PrednisoloneDrug: MercaptopurineDrug: MethylprednisoloneOther: Questionnaire AdministrationDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.